Bernd Hentsch
Direktor/Vorstandsmitglied bei G2M Cancer Drugs AG
Profil
Bernd Hentsch is currently a Director at G2M Cancer Drugs AG since 2001.
He was previously a Chief Development Officer at 4SC AG and TopoTarget UK Ltd.
Dr. Hentsch holds a doctorate degree from Julius-Maximilians-Universität Würzburg.
Aktive Positionen von Bernd Hentsch
| Unternehmen | Position | Beginn |
|---|---|---|
G2M Cancer Drugs AG
 G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Direktor/Vorstandsmitglied | 01.01.2001 |
Ehemalige bekannte Positionen von Bernd Hentsch
| Unternehmen | Position | Ende |
|---|---|---|
| 4SC AG | Corporate Officer/Principal | - |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Bernd Hentsch
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| 4SC AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
TopoTarget UK Ltd.
TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Retail Trade |
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Commercial Services |
